STAT February 8, 2024
Rachel Cohrs

WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater.

The hearing, featuring Merck CEO Robert Davis, Johnson & Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared. Photographers flocked for photos as Sanders shook hands with each executive, standard practice before such hearings begin.

Sanders’ staff got an arm workout switching out foam boards behind the chairman’s head, illustrating how the drug companies called to testify make more revenue from the United States on certain medications than the rest of the world combined.

But the production...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
What to know about Trump's surgeon general nominee
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Trump's pick for CDC director: 10 things to know
Trump tariffs could drive up generic drug costs: 5 takeaways
Senators urge Congress to avert Medicare physician pay cut

Share This Article